Your browser doesn't support javascript.
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor.
Pilewski, Kelsey A; Wall, Steven; Richardson, Simone I; Manamela, Nelia P; Clark, Kaitlyn; Hermanus, Tandile; Binshtein, Elad; Venkat, Rohit; Sautto, Giuseppe A; Kramer, Kevin J; Shiakolas, Andrea R; Setliff, Ian; Salas, Jordan; Mapengo, Rutendo E; Suryadevara, Naveen; Brannon, John R; Beebout, Connor J; Parks, Rob; Raju, Nagarajan; Frumento, Nicole; Walker, Lauren M; Fechter, Emilee Friedman; Qin, Juliana S; Murji, Amyn A; Janowska, Katarzyna; Thakur, Bhishem; Lindenberger, Jared; May, Aaron J; Huang, Xiao; Sammour, Salam; Acharya, Priyamvada; Carnahan, Robert H; Ross, Ted M; Haynes, Barton F; Hadjifrangiskou, Maria; Crowe, James E; Bailey, Justin R; Kalams, Spyros; Morris, Lynn; Georgiev, Ivelin S.
  • Pilewski KA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Wall S; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Richardson SI; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.
  • Manamela NP; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
  • Clark K; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Hermanus T; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
  • Binshtein E; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Venkat R; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Sautto GA; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.
  • Kramer KJ; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Shiakolas AR; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Setliff I; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Salas J; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Mapengo RE; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
  • Suryadevara N; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Brannon JR; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Beebout CJ; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Parks R; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • Raju N; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Frumento N; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Walker LM; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Fechter EF; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Qin JS; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Murji AA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Janowska K; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • Thakur B; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • Lindenberger J; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • May AJ; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • Huang X; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • Sammour S; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • Acharya P; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA; Department of Biochemistry, Duke University, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA.
  • Carnahan RH; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Ross TM; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
  • Haynes BF; Departments of Medicine and Immunology, Duke University, Durham, NC 27710, USA; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • Hadjifrangiskou M; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Crowe JE; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; V
  • Bailey JR; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Kalams S; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Morris L; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.
  • Georgiev IS; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Med
Cell Rep ; 42(2): 112044, 2023 Jan 27.
Article in English | MEDLINE | ID: covidwho-2209948
ABSTRACT
Despite prolific efforts to characterize the antibody response to human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) mono-infections, the response to chronic co-infection with these two ever-evolving viruses is poorly understood. Here, we investigate the antibody repertoire of a chronically HIV-1/HCV co-infected individual using linking B cell receptor to antigen specificity through sequencing (LIBRA-seq). We identify five HIV-1/HCV cross-reactive antibodies demonstrating binding and functional cross-reactivity between HIV-1 and HCV envelope glycoproteins. All five antibodies show exceptional HCV neutralization breadth and effector functions against both HIV-1 and HCV. One antibody, mAb688, also cross-reacts with influenza and coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We examine the development of these antibodies using next-generation sequencing analysis and lineage tracing and find that somatic hypermutation established and enhanced this reactivity. These antibodies provide a potential future direction for therapeutic and vaccine development against current and emerging infectious diseases. More broadly, chronic co-infection represents a complex immunological challenge that can provide insights into the fundamental rules that underly antibody-antigen specificity.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials Topics: Vaccines Language: English Journal: Cell Rep Year: 2023 Document Type: Article Affiliation country: J.celrep.2023.112044

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials Topics: Vaccines Language: English Journal: Cell Rep Year: 2023 Document Type: Article Affiliation country: J.celrep.2023.112044